Korsana Biosciences, Inc. Common Stock
KRSA
70 hedge funds and large institutions have $66.9M invested in Korsana Biosciences, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 12 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
1% more funds holding
Funds holding: 69 → 70 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
3.25% less ownership
Funds ownership: 67.64% → 64.39% (-3.3%)
52% less capital invested
Capital invested by funds: $140M → $66.9M (-$72.6M)
63% less call options, than puts
Call options by funds: $21K | Put options by funds: $57K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$171K |
| 2 |
Two Sigma Investments
New York
|
+$52.5K |
| 3 |
QI
QS Investors
New York
|
+$50K |
| 4 |
D.E. Shaw & Co
New York
|
+$40.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.36M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$553K |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$420K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$272K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$240K |
KRSA Hedge Fund Activity: Q4 2020 in Review
70 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q4 2020, worth a combined $66.9M — down 52% from $140M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new KRSA positions and 12 closed out — a net gain of 1 holder — while 23 added to existing stakes and 19 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $171K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $4.36M sold.
- 70 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q4 2020, up from 69 in Q3 2020.
- Funds reported $66.9M of Korsana Biosciences, Inc. Common Stock stock for Q4 2020, down 52% quarter-over-quarter.
- 13 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q4 2020 and 12 closed out, a net change of +1 holder.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q4 2020 was Morgan Stanley, an estimated $171K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q4 2020 was T. Rowe Price Associates, an estimated $4.36M sold.
Based on aggregated 13F filings for Q4 2020.